Immatics N.V.
General ticker "IMTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Immatics N.V. follows the US Stock Market performance with the rate: 46.8%.
Estimated limits based on current volatility of 2.5%: low 9.13$, high 9.60$
Factors to consider:
- Total employees count: 85 as of 2020
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.26$, 16.38$]
- 2026-12-31 to 2027-12-31 estimated range: [6.01$, 13.79$]
Financial Metrics affecting the IMTX estimates:
- Positive: with PPE of -5.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 18.59 > -0.60
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 86.09 > 64.23
- Positive: Interest expense per share per price, % of 0.09 <= 0.74
Short-term IMTX quotes
Long-term IMTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €54.00MM | €155.84MM | €48.27MM |
| Operating Expenses | €155.72MM | €194.45MM | €230.28MM |
| Operating Income | €-101.72MM | €-38.62MM | €-182.02MM |
| Non-Operating Income | €4.73MM | €59.96MM | €-16.42MM |
| Interest Expense | €0.83MM | €0.89MM | €0.95MM |
| R&D Expense | €118.66MM | €148.08MM | €183.83MM |
| Income(Loss) | €-96.99MM | €21.35MM | €-198.44MM |
| Taxes | €0.00MM | €6.13MM | €-1.99MM |
| Net Income(Loss)* | €-99.34MM | €15.22MM | €-188.69MM |
| Stockholders Equity | €225.08MM | €574.84MM | €483.89MM |
| Assets | €509.96MM | €696.15MM | €562.10MM |
| Operating Cash Flow | €18.23MM | €-158.03MM | €-169.66MM |
| Capital expenditure | €30.96MM | €16.48MM | €6.30MM |
| Investing Cash Flow | €-31.39MM | €-152.39MM | €196.70MM |
| Financing Cash Flow | €84.52MM | €319.68MM | €93.51MM |
| Earnings Per Share** | €-1.23 | €0.14 | €-1.54 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.